The GPT2 Knockout NCI-H1975 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human NCI-H1975 lung adenocarcinoma cell line, designed to disrupt the GPT2 gene encoding mitochondrial alanine aminotransferase. This product provides a robust loss-of-function model for investigating the metabolic roles of GPT2 in a non-small cell lung cancer (NSCLC) context. The polyclonal population preserves heterogeneous genetic backgrounds, enabling studies of collective cellular responses to GPT2 ablation without clonal selection bias.
The parental NCI-H1975 cell line is an adherent epithelial line isolated from a non-smoking female patient with non-small cell lung adenocarcinoma. It harbors activating EGFR L858R and T790M mutations, which drive oncogenic signaling and are frequently associated with acquired resistance to first-generation tyrosine kinase inhibitors. These characteristics make NCI-H1975 a widely employed model for exploring EGFR-mutant NSCLC pathogenesis, drug resistance mechanisms, and metabolic dependencies.
GPT2 encodes the mitochondrial isoform of alanine aminotransferase, which catalyzes the reversible transamination of L-alanine and ??-ketoglutarate to pyruvate and glutamate, a reaction that integrates carbon and nitrogen metabolism. This enzyme functions downstream of regulatory inputs from PPARGC1A, FOXO1, MYC, HIF1A, and mTOR, linking amino acid homeostasis to gluconeogenesis, neurotransmitter cycling, and the urea cycle. GPT2 requires pyridoxal phosphate (PLP) as a cofactor and works in concert with the cytosolic GPT1 and the aspartate aminotransferases GOT1 and GOT2 to balance alanine, glutamate, and ??-ketoglutarate pools. Its activity contributes to pyruvate production, redox maintenance via NADH/NADPH balance, and glutathione synthesis, thereby influencing cellular antioxidant capacity.
In the NCI-H1975 background, GPT2 knockout is expected to perturb mitochondrial alanine catabolism, potentially impairing gluconeogenic flux and altering glutamate/glutamine utilization. Given that NSCLC cells often rely on metabolic plasticity to sustain proliferation under nutrient stress, the loss of GPT2 may sensitize these EGFR-mutant cells to amino acid deprivation or metabolic inhibitors. This model thus provides a relevant system to dissect how mitochondrial transamination influences the metabolic vulnerabilities of lung adenocarcinoma, offering insights into therapeutic strategies that target metabolic dependencies in EGFR-mutant tumors.
Researchers can employ this polyclonal knockout population to investigate the role of GPT2 in metabolic reprogramming, amino acid dependency, and drug resistance in NSCLC. Typical experimental approaches include metabolic flux analysis using isotopically labeled alanine or glutamine, Seahorse profiling to assess mitochondrial respiration and glycolysis, cell viability and apoptosis assays under amino acid starvation, and glutaminase activity measurements. The model also enables screening for synthetic lethal interactions or drug sensitivities that arise from GPT2 disruption. For further information or support, please contact Ascent Research.
